Cas9 cannot cut just anywhere - it requires a short motif called a PAM next to its target - and that constraint limits which sites are editable. US11286468B2 - "Engineered CRISPR-Cas9 nucleases with altered PAM specificity," issued March 29, 2022 to The General Hospital Corporation (inventors Joung, Kleinstiver) - claims variants that relax or redirect that constraint.
The protospacer-adjacent motif (PAM) is the genome's gatekeeper for Cas9: no PAM nearby, no cut. Wild-type SpCas9 needs an 'NGG' motif, which leaves swaths of the genome inaccessible. The claimed invention re-engineers the protein so it recognizes different PAMs, and that altered recognition is the limitation that defines the claim's scope.
Why does PAM engineering matter commercially? Many therapeutically important mutations sit at sites without a conveniently placed NGG. A variant with broadened PAM specificity makes those sites editable, which is the difference between a treatable and an untreatable target. The value of the claim is the expanded addressable space, not a new cutting mechanism.
The claim-scope question is precise: it turns on the specific amino-acid substitutions that confer the altered PAM recognition. A competitor's Cas9 variant infringes only if its engineered residues fall within the claimed set or their equivalents. Describing this patent as 'a Cas9 patent' badly understates the specificity - the claim is about which residues were changed to read which motif.
For the landscape, PAM-engineering grants are a distinct sub-estate within the CRISPR thicket. They do not compete with the foundational Cas9 composition claims - they layer on top, expanding the tool's reach. Any program that needs to edit a PAM-poor site has to navigate this layer separately from the core machinery patents.